Saltar a la navegació principal
Saltar a la cerca
Vés al contingut principal
Portal de Recerca de la Universitat Autònoma de Barcelona Inici
Ajuda i PMF
Català
Español
English
Inici
Perfils
Unitats de recerca
Projectes
Producció científica
Conjunts de dades
Tesis doctorals
Cerca per experiència, nom o afiliació
Acute lymphoblastic leukemia
Josep Maria Ribera
Departament de Medicina
Producció científica
:
Capítol de llibre
›
Capítol
›
Recerca
›
Avaluat per experts
6
Cites (Scopus)
Informació general
Fingerprint
Fingerprint
Navegar pels temes de recerca de 'Acute lymphoblastic leukemia'. Junts formen un fingerprint únic.
Ordenar per
Ponderació
Alfabèticament
Keyphrases
AIDS/HIV
100%
Acute Lymphoblastic Leukemia
100%
Neoplasms
33%
Antiretroviral Therapy
33%
Human Immunodeficiency Virus Infection
33%
United States
16%
Cancer Incidence
16%
Emerging Problems
16%
Leukemia
16%
Infected People
16%
Infected Patients
16%
Prospective Observational Study
16%
Clinical Characteristics
16%
Standardized Incidence Ratio
16%
Burkitt
16%
Nonimmunocompromised Patients
16%
AIDS-defining Illness
16%
Large Cohort Study
16%
Non-AIDS Events
16%
Biologic Characteristics
16%
Immunosuppressed Individuals
16%
Data Matching
16%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Acute Lymphoblastic Leukemia
100%
Malignant Neoplasm
50%
Neoplasm
33%
Antiretroviral Therapy
33%
Human Immunodeficiency Virus Infection
33%
Population
16%
Immunocompromised Patient
16%
Observational Study
16%
Standardized Incidence Ratio
16%
Cancer
16%
Leukemia
16%
Nursing and Health Professions
Human Immunodeficiency Virus
100%
Acute Lymphoblastic Leukemia
100%
Malignant Neoplasm
50%
Human Immunodeficiency Virus Infection
33%
Neoplasm
33%
Antiretroviral Therapy
33%
Leukemia
16%
Population
16%
Immunocompromised Patient
16%
Standardized Incidence Ratio
16%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Acute Lymphoblastic Leukemia
100%
Malignant Neoplasm
50%
Neoplasm
33%
Human Immunodeficiency Virus Infection
33%
Observational Study
16%
Leukemia
16%
Immunocompromised Patient
16%
Standardized Incidence Ratio
16%